| Date | Title | Description |
| 06.08.2024 | Cellectis Provides Financial Results for the Second Quarter 2024 | ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL
ODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatment
Cash position of $273 million as of June 30, 20241; cash runway ... |
| 05.06.2024 | Nucleus RadioPharma Secures Investment from AstraZeneca | What You Should Know:
– Nucleus RadioPharma, the world’s first comprehensive radiopharmaceutical organization, today announced the closing of an extended Series A funding round with the addition of new investor AstraZeneca.
– The strategic ... |
| 29.04.2024 | Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023 | • Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting
• Execution of strategic collaboration and investment agreements with Ast... |
| 08.03.2024 | CAR T-Cell Therapy Market Set for Healthy Growth after COVID19 Pandemic Top Players Industry Trends and Forecast 2032 | CHICAGO, UNITED STATES, March 8, 2024 /EINPresswire.com/ -- Astute Analytica, a leading provider of market research and analysis, released its highly anticipated Market Analysis Report on the Global 𝐂𝐀𝐑 𝐓-𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭. This comprehen... |
| 16.01.2024 | Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB) | - |
| 16.01.2024 | Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB) | NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,... |
| 04.05.2023 | Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023 | First r/r ALL patient dosed in Europe with Cellectis’ UCART22 product candidate manufactured in-house Cellectis implements CLLS52 for the first time in the clinic with Sanofi’s alemtuzumab Cellectis stops enrollment and treatment of patient... |
| 28.12.2022 | Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities | - |
| 28.12.2022 | Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities | The credit facility will enable Cellectis to support the development of its UCART product candidates pipeline
The credit facility consists of three tranches of €20 million, €15 million, and €5 million respectively, each redeemable in fine i... |
| 12.10.2022 | Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022 | NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cellectis (the "Company") CLLS, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that the... |
| 27.04.2022 | Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics | Cellectis is developing custom TALEN® for Cytovia to develop gene-edited iPSC-derived Natural Killer cells
Cytovia and Isleworth Healthcare Acquisition Corp. announce business combination agreement and combined company is expected to be lis... |
| 15.03.2022 | Iovance Biotherapeutics’ Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV ... | Clinical Study Expected to Begin in 2022 to Investigate the Safety and Efficacy of IOV-4001 to Deliver TIL and PD-1 Inhibition within a Single Cancer Therapy
First Genetically Modified Iovance TIL Therapy Leverages TALEN® technology License... |
| 04.11.2021 | Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021 | • Sponsored programs at ASH 2021 - preliminary clinical data to be presented at ASH 2021 for product candidate UCART22 and preclinical data from Cellectis gene therapy product candidate TALGlobin01
• Partnered programs at ASH 2021 – ALPHA2 ... |
| 04.11.2021 | Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021 | Sponsored programs at ASH 2021 - preliminary clinical data to be presented at ASH 2021 for product candidate UCART22 and preclinical data from Cellectis gene therapy product candidate TALGlobin01
Partnered programs at ASH 2021 - ALPHA2 and ... |
| 27.08.2021 | Cellectis S A : Announces Participation in Five Investor Conferences (Form 6-K) | Cellectis Announces Participation in Five Investor Conferences
NEW YORK, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS - EURONEXT GROWTH: ALCLS) (the 'Company'), a gene-editing platform company with clinical-stage immuno-on... |
| 10.08.2021 | Bringing immuno-oncology cell therapies to the masses – are we (nearly) there yet? | |
| 28.03.2019 | Pontifax AgTech Achieves 2nd Exit as Precision Biosciences IPOs with $870m Valuation | Precision Biosciences, the gene-editing startup, started trading on the Nasdaq stock exchange today after raising a $126.4 million IPO, valuing the company at $870 million.
The IPO will achieve an exit for growth stage agrifood tech investo... |
| 29.10.2018 | The West is losing the gene editing race. It needs to catch up | The Soviet Union’s successful launch of Sputnik I, the world’s first artificial satellite, in 1957 caught the Western world off guard. Yet within a dozen years, a U.S. astronaut was walking on the moon.
I fear that the West is losing today’... |
| 11.04.2018 | Cellectis raises $164M for CAR-T and gene-editing programs | After a tricky patch in 2017, the stars seem to be coming back into alignment for French CAR-T specialist Cellectis, which has just closed a $164 million U.S. public offering.
Around $100 million of the new funding will be used to build com... |
| 30.10.2017 | Gene editing remains early stage, but Big Pharma has taken notice | In its recent report, titled Gene Editing: The Next Breakthrough in Regenerative Medicine, Informa Pharma Intelligence answers those questions with a focus on three major existing technologies: CRISPR/Cas9, zinc-finger nucleases (ZFNs), and... |
| 06.10.2017 | David Meeker starts a new biotech chapter in his career; Sam Kulkarni takes the helm at CRISPR | → David Meeker left Genzyme last April after a 23-year run, including six years as president after Sanofi stepped in to buy the landmark biotech six years ago. Five months later, after adding a string of biotech board positions... |
| 08.09.2017 | Ag Industry Brief: AeroFarms Gets $1m FFAR Grant, Nestle Acquires Plant Burger Company, Impossible Opens Facility, more | AeroFarms Gets $1m Grant From FFAR
New Jersey-based indoor vertical farming company AeroFarms has received a $1 million research grant from The Foundation for Food and Agriculture Research (FFAR), a nonprofit organization established throug... |
| 28.07.2017 | Gene Editing Gets Public Market Approval as Calyxt Raises $64m IPO | Gene editing has caused a lot of excitement in agriculture technology circles for its potential to produce crops, and even animals, with improved characteristics. The technique, which enables undesirable traits — such as intolerance to heat... |
| 28.06.2017 | Gene therapy upstart lands $45M round; Biogen picks new communications chief | → A syndicate led by Arix Bioscience backed a big, $45 million round for LogicBio, an upstart gene therapy biotech focused on rare pediatric diseases. OrbiMed, Edmond De Rothschild Investment Partners, Pontifax, and SBI... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 20.05.2016 | Reshaping human health and changing lives through gene editing | André Choulika Contributor
André Choulika is chairman and CEO of Cellectis.
Gene editing is going to fundamentally change our lives and how we traditionally think about health throughout the first half of the 21st century.
Gene editing is g... |
| 11.08.2015 | CRISPR: Editas’ $120M proves it isn’t a bunch of hype. Here are 6 more biotechs shaping CRISPR landscape | But that’s already turned quickly on its head.
Confidence is growing in the technology, as evidenced by the title of a fantastic Wired article: “Easy DNA Editing Will Remake the World. Buckle Up.” And the broader scientific community is now... |
| 26.07.2011 | Minnesota ‘biotech incubator’ UEL has failed. It’s time to admit it | But UEL appears to want another shot at reclaiming its biotech incubator mantle. It wants state help for a $27 million expansion, which would include more wet lab space.
That wouldn’t be prudent. And unless there are major changes, the term... |
| - | Minnesota ‘biotech incubator’ UEL has failed. It’s time to admit it | It’s time to call the $24 million University Enterprise Laboratories Inc. what it is: a successful landlord.
During the past six years, UEL has portrayed itself as a biotech incubator helping the University of Minnesota’s technology transfe... |
| - | Gene editing remains early stage, but Big Pharma has taken notice | The field of gene editing is moving fast. In late October, two new papers described technologies that allow for the precise editing of individual DNA bases — an A to a T, a C to a G — and, separately, a mechanism for genetically editing RNA... |
| - | CRISPR: Editas’ $120M proves it isn’t a bunch of hype. Here are 6 more biotechs shaping CRISPR landscape | CRISPR/Cas9 gene editing has zoomed to the forefront of the biotech investment scape in the past year — punctuated this week by Editas Medicine‘s impressive $120 million fundraise. Looks like it’s no longer hype — there’s solid funding to p... |
